Acute Ischemic Stroke Clinical Trial
— PROTECT-MTOfficial title:
PROximal TEmporary oCclusion Using Balloon Guide Catheter for Mechanical Thrombectomy(PROTECT-MT)
Verified date | January 2024 |
Source | Changhai Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A multi-center, prospective, randomized, open-label, blinded endpoint assessment (PROBE) clinical trial of endovascular treatment among selected AIS.
Status | Suspended |
Enrollment | 1074 |
Est. completion date | December 31, 2024 |
Est. primary completion date | June 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age 18 years or older 2. Acute ischemic stroke, caused by a large vessel occlusion of the anterior circulation cerebral artery confirmed on brain imaging (intracranial carotid artery or middle M1/proximal M2) 3. Femoral artery puncture can be finished within 24 hours of symptom onset based on local practice 4. Pre-event modified Rankin Scale score 0-1 5. Written informed consent obtained (by patient or appropriate proxy, according to local requirements) Exclusion Criteria: 1. Intracranial hemorrhage on imaging 2. Known or suspected pre-existing (chronic) large vessel occlusion in the symptomatic territory 3. Excessive vascular access tortuosity that navigating BGCs would be impossible 4. Intracranial stent implanted in the same vascular territory that precludes the safe deployment/removal of the neuro-thrombectomy device 5. Any other condition precludes performing MT procedure 6. Occlusions in multiple vascular territories confirmed on CTA/MRA 7. Pregnancy 8. Allergy to contrast agents 9. Patients refuse to cooperate or unable to tolerate interventional operation 10. Expected lifetime<90 days 11. Unlikely to participate in follow-up assessments 12. Any other condition that, in the opinion of the investigator, not suitable for BGCs |
Country | Name | City | State |
---|---|---|---|
China | Jianimin Liu | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Changhai Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Death | Deaths at 90 days (±14 days) post treatment | 90 days | |
Other | Intracerebral hemorrhage (ICH) | Intracranial hemorrhage, symptomatic intracranial hemorrhage or asymptomatic intracranial hemorrhage at 7 days post treatment or discharge (whichever occurs first) | 7 days post treatment or discharge (whichever occurs first) | |
Other | SAE | Other serious adverse events (SAEs) adjudicated by the Clinical Events Committee | 90 days | |
Other | perioperative complications | Any perioperative complications such as bleeding transformation, cerebral edema, vascular re occlusion, vascular dissection, new watershed embolism, contrast agent extravasation, puncture site hematoma, vascular spasm, vascular rupture, perforating branch tear, vascular perforation, stress ulcer, contrast agent hypersensitivity, contrast agent nephropathy, etc. | Perioperative period | |
Primary | Functional outcome | defined as modified Rankin Scale (mRS) | 90 days | |
Secondary | Dichotomized mRS | Dichotomized mRS (0-1 versus 2-6,0-2 versus 3-6,0-3 versus 4-6,0-4 versus 5-6,0-5 versus 6) | 90 days | |
Secondary | Change in stroke severity | NIHSS | 24 hours post treatment | |
Secondary | Change in stroke severity | NIHSS | 7 days post treatment or discharge (whichever occurs first). | |
Secondary | Technical success rate | defined as successfully navigating the guide catheter into target vessel, and finishing the MT procedure without changing another guide catheter | 24 hours after MT | |
Secondary | Reperfusion outcome | (eTICI 2b or greater ,eTICI 2c or greater, eTICI 3)in Final angiogram. | 24 hours after MT | |
Secondary | Reperfusion result | (eTICI 2b or greater ,eTICI 2c or greater, eTICI 3) after First pass | 24 hours after MT | |
Secondary | Time from groin puncture to successful reperfusion | ( eTICI 2c or greater) | 24 hours after MT | |
Secondary | Revascularization quality | (eTICI 2c or greater) within 45 min of access | 24 hours after MT | |
Secondary | Thrombectomy attempt (final) | Number of MT (final) | 24 hours after MT | |
Secondary | Occurrence of emboli to a new territory | Occurrence of emboli to a new territory | 90 days | |
Secondary | Final infarct volume | Final infarct volume at 5-7 days | 5-7 days after MT |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Not yet recruiting |
NCT06437431 -
Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy
|
Phase 2/Phase 3 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 |